Compare stocks

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company focuses on developing treatments for gastrointestinal and metabolic diseases, including obesity and diabetes. Its product portfolio includes innovative solutions like dasiglucagon, intended for severe hypoglycemia. Founded in 1998, Zealand Pharma leverages proprietary peptide platforms to address unmet medical needs. The company's strategic positioning involves strong partnerships and collaborations with pharmaceutical companies to advance its products through various stages of clinical development.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.